Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.

Monocentric study composed by 2 steps : 1. First step is a phase I with the aim of establish the recommended dose of mirdametinib administration (2 or 4 mg twice a day for 7 or 14 days per cycle for the 4 first of carboplatin/pemetrexed/pembrolizumab treatment) 2. Second step is a non comparative randomized (2:1) phase II trial testing the recommended dose of mirdametinib administration. The aim is the efficacy and safety of short course of mirdametinib treatment for the 4 first cycles of the carboplatin/pemetrexed/pembrolizumab treatment.

NCT Number	NCT05937906
Lead Sponsor	Centre Georges Francois Leclerc
Conditions	Non-Small Cell Lung Cancer
Enrollment	24 participants
Start Date	2026-07-07
Primary Completion	2028-07-25 (estimated)
Study Completion	2029-05-25 (estimated)
Updated on ClinicalTrials.gov	2026-07-09